Interview with Tomáš Matějovský, Partner, CMS Cameron McKenna Czech…
Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated…
Address: CMS Cameron McKenna v.o.s. Palladium, Na Poříčí 1079/3a 110 00 Prague 1,Czech Republic
Tel: +420 296 798-111
Web: http://www.cms-cmck.com/Prague-Czech-Republic
The Prague office of CMS was established in 1991. The office has over 35 international and local lawyers and provides a full range of legal services to both domestic and international clients. We conduct regular independent reviews with clients and these indicate that they value our ability to combine international expertise with local knowledge.
We have significant experience in working with international and local companies, insurers, banks and financial institutions, private organizations and government authorities. CMS in Prague is considered a market leader and our experts, such as Tomáš Matějovský, receive excellent feedback from clients.
CMS Cameron McKenna has a track record of advising lifesciences businesses throughout Central and Eastern Europe. We have been established in the region for more than twenty years, which means we never underestimate the differences between local markets, whilst taking into account EU and EEA standards.
Over the past years sector regulations in the region have undergone significant changes – from the rules on marketing pharmaceutical and healthcare products to legislation relating to medical devices. The changes have had a profound effect on the way business is conducted in CEE. We’ve made it our business to know the market inside out.
Our clients tell us that we have the in-depth knowledge they need to support their businesses across the region. We speak the industry’s language and our cross-regional lifesciences practice comprises 50+ lawyers advising some of the sector’s major players and representatives.
Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated…
The latest pharma news from Central and Eastern Europe (CEE), including a new report on the disparities between the region’s healthcare systems and those of Western Europe; why US companies…
Roman Grunt, CEO of Quinta Analytica, gives us an overview of the activities of how the Czech firm has managed to attract customers across the country and beyond by positioning…
PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Czech Republic is available for download now. Home to a USD 3.38 billion pharma market, one of Central and Eastern Europe’s…
Key stakeholders within the Czech medtech industry highlight how medical devices can improve efficiency and quality of care across the country’s healthcare landscape, why greater levels of collaboration are of…
Roman Samiec, general manager of Thuasne Czech Republic, introduces the company as a key competitor in the medical devices field, with their niche products addressing the unmet medical need in…
Miroslav Palát, president of CzechMed, the medical device association in the Czech Republic, and Jiří Pavlíček, who combines the responsibility of Chairman of the association and CEO of the medtech…
Pavla Nevolová, country head of EastHORN in the Czech Republic, shares the historical roots of the now multinational Czech CRO. Nevolová also shares her insights into the recent evolution of…
The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning that it stands out as one of Central and Eastern Europe’s top destinations for clinical…
In 1996 Jiří Žák, chairman & current CEO of FARMAK, borrowed half a billion Czech crowns to take over a state-owned producer of vitamins for which he had started working…
As one of the few pharma companies in the Czech Republic to offer products across the whole healthcare spectrum, including prescription drugs, generics, over-the-counter (OTC) treatments, and food supplements, the…
Roman Dusil, GM of Pierre Fabre Laboratories in the Czech Republic and Slovakia, shares how the Czech affiliate is ahead of Pierre Fabre’s global transformation of the convergence between the dermo-cosmetic…
Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before…
See our Cookie Privacy Policy Here
